press release

May 5, 2017

CAMBRIDGE, Mass., Feb 24, 2009 (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY): Established Human Proof of Concept with an RNAi Therapeutic, a First for the Industry Advanced Pipeline with ALN RSV and ALN VSP Clinical Programs Continued Scientific Leadership, Consolidation of Leading Intellectual Property, and Formed Four Major Alliances in Last 12 Months with $175 Million in Realized ...

press release

May 5, 2017

Regulus Therapeutics Receives $20 Million in a Series A Equity Financing CARLSBAD, Calif. & CAMBRIDGE, Mass. (BUSINESS WIRE) Regulus Therapeutics Inc., Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) announced today that Regulus has raised $20 million in a Series A preferred equity financing that further strengthens its balance sheet. Alnylam and Isis were the sole and equal investors in ...

press release

May 5, 2017

CAMBRIDGE, Mass. (BUSINESS WIRE) May. 7, 2009 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2009 and company highlights. “This past quarter has been very productive, as we have executed across all dimensions of our company’s key value drivers – scientific leadership, clinical pipeline, ...

press release

May 5, 2017

CAMBRIDGE, Mass. (BUSINESS WIRE) Aug. 6, 2009 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) Advances Pipeline of RNAi Therapeutics with Phase II Results for ALN RSV01, Initiation of First Systemic Delivery Program with ALN VSP for Liver Cancer, and Designation of ALN TTR for Amyloidosis as Next IND Candidate – Achieves Continued Progress on Delivery of RNAi Therapeutics, Including New Research Alliances ...

press release

May 5, 2017

Alnylam Provides Organizational UpdateCAMBRIDGE, Mass., Aug 21, 2009 (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that John (Jack) A. Schmidt, Jr., M.D., Chief Scientific Officer is leaving the company. "We wish Jack well in his future endeavors," said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. "Without a doubt, we have ...

press release

May 5, 2017

CAMBRIDGE, Mass. (BUSINESS WIRE) Nov. 9, 2009 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will webcast its upcoming R&D Day live on the “Investors” section of the company’s website at www.alnylam.com. Alnylam scientists and management will review and provide updates on Alnylam platform advancements, delivery strategies, and pipeline of novel RNAi therapeutics. ...

press release

May 5, 2017

Alnylam and Roche Advance RNAi Therapeutic Collaboration Phase of Landmark 2007 Alliance– Partners to Co Develop and Co Commercialize Certain RNAi Therapeutic Products in U.S. Market – – Collaboration to Include Alnylam Lipid Nanoparticle and Roche Dynamic Polyconjugate Delivery Technologies – CAMBRIDGE, Mass. (BUSINESS WIRE) Nov. 4, 2009 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today ...

press release

May 5, 2017

CAMBRIDGE, Mass. (BUSINESS WIRE) Nov. 4, 2009 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2009 and company highlights. "Activities this quarter reflect the substantial progress we are making as we continue to lead the industry's efforts in the discovery and development of RNAi ...

press release

May 5, 2017

Alnylam Pharmaceuticals Reports Fourth Quarter and 2007 Financial Results Completed 2007 with $455.6 Million in Cash and Achieved Over $50 Million in Revenues Advanced ALN RSV01 Program through Phase II Development with Positive Results Forged Major Alliance with Roche and Formed Regulus Therapeutics Joint Venture Continued Scientific Leadership and Consolidation of Leading Intellectual Property CAMBRIDGE, Mass., Feb 07, 2008 (BUSINESS ...

press release

May 5, 2017

Alnylam Forms New Agreement with Tekmira Related to the Planned Tekmira Protiva Business CombinationTekmira Pharmaceuticals and Protiva Biotherapeutics Announce Business Combination to Create New Company Focused on RNAi Delivery and Therapeutics New Agreement Expands Alnylam's Access to Key Technologies and Intellectual Property for Systemic Delivery of RNAi Therapeutics Alnylam to Invest $5 Million in New Combined Company CAMBRIDGE, Mass. (BUSINESS WIRE) ...